Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab—A Case Report

Journal of Stroke and Cerebrovascular Diseases

Volumn 25, Issue 8, 2016, Pages e126-e127

  Schäfer, Niklas ^a   Müller, Andreas ^a   Wüllner, Ullrich ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

atrial fibrillation; dabigatran; Idarucizumab; ischemic stroke; systemic thrombolysis

Indexed keywords

ALTEPLASE; DABIGATRAN; IDARUCIZUMAB; ANTITHROMBIN; MONOCLONAL ANTIBODY;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BRAIN INFARCTION; BRAIN ISCHEMIA; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED SCINTIGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; EMERGENCY CARE; FEMALE; FIBRINOLYTIC THERAPY; HEMIPARESIS; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MIDDLE CEREBRAL ARTERY OCCLUSION; PERMANENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; THROMBIN TIME; COMPLICATION; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC IMAGING; STROKE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTITHROMBINS; BRAIN ISCHEMIA; DABIGATRAN; FEMALE; HUMANS; STROKE; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 84969641397     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2016.05.006     Document Type: Article

References (2)

1. 1 Glund, S., Stangier, J., Schmohl, M., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386 (2015), 680–690.
2. 2 Pollack, C.V. Jr, Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.